PharmEasy IPO or Thyrocare Merger: API Puts Profit First

API Holdings, the parent of PharmEasy, is weighing an initial public offering (IPO) or a potential merger with Thyrocare. In an interview report published on 5 October 2026, managing director and CEO Rahul Guha said profitability in the business excluding Thyrocare would come before choosing a route.

The discussion follows the group's August announcement that it had repaid ₹1,050 crore of term debt. The October interview leaves the listing route open; it does not announce an IPO date or an agreed Thyrocare merger.

August Debt Repayment and Thyrocare Control

On 17 August 2026, API Holdings announced that it had repaid the term debt using proceeds from a partial Thyrocare stake sale and internal accruals. The group retained a 51.02% stake in the listed diagnostics company, preserving control.

Clearing that borrowing removes its associated financing burden. The reported repayment concerns term debt, rather than every liability or any future working-capital borrowing.

What the Q1 FY27 Numbers Show

API Group's provisional, unaudited Q1 FY27 presentation reported revenue of ₹1,754 crore and adjusted EBITDA of ₹39.3 crore. EBITDA means earnings before interest, tax, depreciation and amortisation; this adjusted figure also excludes employee stock-option and impairment costs.

The group recorded an adjusted pre-tax loss of ₹29.6 crore, excluding employee stock-option costs. Positive adjusted EBITDA therefore did not amount to a net profit after all expenses and tax.

These management-presentation figures cover the quarter before the August repayment and October interview. They provide historical financial context, rather than a measure of profitability on the interview date.

What the Options Mean for API Shareholders

For holders of PharmEasy unlisted shares, an API Holdings IPO and a Thyrocare merger would involve different transaction structures. The interview gives no merger terms or share-swap ratio—the number of shares holders might receive in an exchange.

A formal route decision and transaction disclosures would be needed to establish the implications for existing shareholders. Management's discussion of options alone does not establish a listing timetable or an automatic exit.

Sources

• Moneycontrol — PharmEasy IPO and merger interview report, 5 October 2026. Source for Guha's reported listing options and profitability priority.
• Moneycontrol — API Holdings debt repayment and retained Thyrocare control, 17 August 2026. Source for the repayment, funding sources and retained stake.
• API Holdings — Q1 FY27 Investor Presentation, August 2026, page 5. Source for provisional, unaudited API Group revenue, adjusted EBITDA and adjusted pre-tax result. INR-million figures converted to crore.

Disclosure

Unlisted Valley facilitates transactions in unlisted shares and may have a commercial interest in the companies covered. This report is for information and is not investment advice.